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THESIS ABSTRACT 
 
Background 
 
Autoimmune bullous dermatoses present with overlapping clinical features 
that require histopathological correlation. Immunofluorescence is the most 
routinely used reliable investigation for diagnosis but requires specialised 
equipment and is technically sophisticated. Collagen IV 
immunohistochemistry is reported as a reliable test for the diagnosis of 
epidermolysis bullosa acquisita whereby It stains the roof of a subepidermal 
blister and would be expected on the floor in bullous pemphigoid. This 
technique could be performed as an easily accessible alternative to direct 
immunofluorescence and has been used anecdotally at our hospital. 
 
Aim 
 
To investigate whether collagen IV immunohistochemistry can be used as a 
reliable histopathological confirmation of bullous pemphigoid. 
 
Methods 
 
Two major investigations: 
1. A systematic literature search was undertaken of all studies describing 
the use of collagen IV immunohistochemistry and those comparing it 
with immunofluorescence in the diagnosis of bullous pemphigoid.  
2. A retrospective study of patients diagnosed with bullous pemphigoid 
over 12 years seen at Groote Schuur Hospital was performed. Patient 
records that had results for both direct immunofluorescence and 
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collagen IV immunohistochemistry were selected. The positive 
percentage agreement was calculated. 
 
Results 
 
1. Two studies were found that investigated the use of collagen IV 
immunohistochemistry in bullous pemphigoid. All reported 33 (100%) 
cases demonstrated collagen IV at the floor of a subepidermal blister. 
Of these, 25/25 cases were in agreement with direct 
immunofluorescence and 7/8 with indirect immunofluorescence which 
were used as reference standard investigations. 
2. In this study, collagen IV was positive in 96% (79/82) of cases and 
direct immunofluorescence was positive in 85% (72/82) of cases. A 
positive percentage agreement of 80.5% suggested a strongly positive 
test accordance. 
 
Limitations 
 
1. The literature search was limited to articles written in english only. 
2. The retrospective design and the lack of controls without bullous 
pemphigoid made it impossible to calculate sensitivity and specificity 
as well as the kappa statistic. 
 
Conclusion 
 
Collagen IV immunohistochemistry is a valid, simple and widely available test 
which demonstrates accordance with routinely used direct 
immunofluorescence in the confirmation of bullous pemphigoid. Through 
clinical and histomorphological correlation, it may be a useful test in 
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resource-limited settings without facilities for direct immunofluorescence. 
However, larger controlled studies are warranted to confirm this. 
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INTRODUCTION AND LITERATURE REVIEW 
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1. INTRODUCTION
1.1 Background 
Autoimmune cutaneous blistering disorders may present with overlapping 
clinical features that require histopathological correlation to confirm the 
diagnosis.  Direct immunofluorescence is used routinely in this regard but 
requires specialised equipment and is technically sophisticated, thus it is not 
widely available particularly in poor countries. Therefore, there is a need for 
other more easily accessible and accurate diagnostic tests for such disorders 
including bullous pemphigoid. In epidermolysis bullosa acquisita (EBA), a 
clinical differential diagnosis of bullous pemphigoid, collagen IV 
immunohistochemistry has already been used as a reliable and readily 
available confirmatory test by staining the roof of a subepidermal blister. 
Similarly, this technique may be used in the diagnosis of bullous pemphigoid 
by staining the floor of a subepidermal blister. Hence immunohistochemistry 
may offer an alternative to immunofluorescence in bullous pemphigoid. There 
is sparse literature in this regard thus the aim of this study is to investigate 
whether collagen IV immunostaining can be used as a reliable 
histopathological confirmation of clinical bullous pemphigoid. 
1.2 Bullous pemphigoid 
1.2.1 Definition and pathogenesis 
Bullous pemphigoid is an acquired autoimmune blistering disorder of the skin 
characterised by large, tense cutaneous bullae. Attachment of autoantibodies 
against hemidesmosomal antigens namely BP230 (bullous pemphigoid 
antigen 1) and BP180 (bullous pemphigoid antigen 2 or collagen XVII) at the 
dermo-epidermal junction cause formation of subepidermal bullae, which can 
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be identified on histology of the skin.(1-3) Binding of the autoantibodies to 
these target-antigens results in complement activation, which in turn induces 
mast cell degranulation. It is also thought that immunoglobulin E (IgE) BP180 
antibodies are bound to eosinophils and mast cells in lesional tissue of 
bullous pemphigoid. Exposure of the NC16A region of BP180 to these cells 
then causes mast cell degranulation thus releasing chemical mediators that 
recruit neutrophils and eosinophils to target tissue. Finally, proteolytic 
enzymes which breakdown dermal-epidermal cohesion and contribute to 
blister formation, are released by neutrophils and eosinophils which 
accumulate at the basement membrane.(4)  
Neurological disease such as cerebrovascular disease, dementia, 
Parkinson’s disease, epilepsy and multiple sclerosis have been reported as 
risk factors for developing bullous pemphigoid thus indirectly contributing to 
morbidity and mortality.(2) Bullous pemphigoid antigens or their isoforms 
have been detected in brain and neuronal tissue and it has been postulated 
that cross-reactivity of autoantibodies with brain and cutaneous antigens as 
well as exposure of hidden antigens in the brain cause an immune response. 
However, recent studies have not been able to confirm this mechanism.(5, 6) 
Possible triggering factors of bullous pemphigoid in those with neurologic 
disease include drug intake, pressure sores, traumatic events and immunity 
aging.(6)  
In a minority of bullous pemphigoid cases, other recognisable inducing 
factors can be identified. Various drugs (particularly those with sulfhydryl 
groups), physical agents, viral infections and diet have been associated with 
bullous pemphigoid in genetically predisposed individuals.(4) 
1.2.2 Clinical Presentation 
Bullous pemphigoid occurs equally in both sexes and most commonly affects 
the elderly but it also presents in the young, particularly children.(2, 7) Tense 
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cutaneous bullae overlying erythematous or normal-appearing skin that heal 
without scaring are typical of bullous pemphigoid (Figures 1-2).  Blisters may 
be localised or generalised with a tendency to involve flexural surfaces and 
may contain clear or blood-stained fluid. This may be preceded by weeks to 
months with erythema and/or urticarial plaques which may or may not be 
pruritic. The oral mucosa, more frequently than genital mucosa, may also be 
involved with small tense blisters or erosions in up to 50% of cases.(1-3, 7) 
Rare atypical presentations of bullous pemphigoid have been described 
including annular erythema-like, erythema multiforme-like, pemphigoid 
nodularis, lichen planus pemphigoides, vesicular, erythrodermic, 
dyshidrosiform and vegetans bullous pemphigoid. Localised variants include 
pretibial, vulvar and umbilical bullous pemphigoid. (8) 
1.2.3. Differential Diagnoses 
There are several other blistering disorders of the skin with differing 
aetiologies, pathogeneses and prognoses which may sometimes mimic 
bullous pemphigoid.(9) These include autoimmune blistering disorders such 
as linear IgA bullous dermatosis, cicatricial pemphigoid, pemphigoid 
gestationis and bullous lupus erythematosus. Genetic bullous disorders such 
as the epidermolysis bullosa group and other conditions such as insect bite 
allergy, burns, erythema multiforme, contact dermatitis and certain viral and 
bacterial infections may also present with blistering.(2) In practice, patients 
do not always present with classical morphology and distributions. This may 
be due to the severity and stage of disease at the time of examination as well 
as the effect of previous treatments used, further complicating the clinical 
picture.(10-12) The management of each condition will differ; therefore an 
accurate diagnosis is essential.  
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1.2.4 Investigations in bullous pemphigoid 
Histopathology (routine): 
The diagnosis of bullous pemphigoid is often suspected clinically but should 
be correlated histopathologically.(3, 7, 10, 11, 13, 14) Subepidermal clefting 
with a mixed dermal inflammatory infiltrate predominantly containing 
eosinophils and occasionally neutrophils are demonstrated on histology of a 
fresh blister that is formalin fixed, paraffin embedded before sectioning and 
stained with haematoxylin and eosin (H&E) (Figures 3-4). However, the most 
widely used reliable confirmation is achieved with immunopathology by direct 
or indirect immunofluorescence.(2, 3, 7, 12, 15)
Immunofluorescence: 
Direct immunofluorescence is performed on perilesional skin where immune 
deposits are most readily detected and specimens are transported fresh, in 
normal saline or in Michel’s transport medium to the laboratory where they 
are cryostat embedded for frozen sectioning.(2, 3, 7, 9, 12) This technique 
involves the conjugation of an antibody with a fluorochrome that is directed 
against a tissue antigen (manually or via automation) and detected using 
ultraviolet light microscopy.(12, 16) The site, strength and pattern of 
deposition of the immune complexes will accurately diagnose the relevant 
autoimmune bullous dermatosis. Linear deposits of immunoglobulin G (IgG) 
autoantibodies and or complement 3 (C3) will be detected at the dermo-
epidermal junction in bullous pemphigoid (Figures 5-6).(2, 3, 7, 9, 12, 16) 
The differential diagnosis for the deposition of IgG and or C3 at the basement 
membrane zone in a subepidermal blister other than bullous pemphigoid 
includes cicatricial pemphigoid, pemphigoid gestationis, epidermolysis 
bullosa acquisita and bullous lupus erythematosus. Hence, in order to 
differentiate bullous pemphigoid from other autoimmune bullous dermatoses, 
the salt split-skin technique combined with immunofluorescence can be used. 
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This technique has the advantage of improving the sensitivity of direct 
immunofluorescence.(2, 3, 7, 11, 13, 15) Skin is incubated in one molar 
sodium chloride solution resulting in separation of the epidermis from the 
dermis at the level of the lamina lucida at the basement membrane zone. In 
this way, immunofluorescent deposits of antibodies become visible on the 
epidermal side of the blister as seen in bullous pemphigoid in more than 90% 
of patients (2, 3, 7, 11, 13, 15, 17) and on the dermal side of the blister in 
EBA, bullous systemic lupus erythematosus and cicatricial pemphigoid.  
Direct immunofluorescence specimens can be processed manually if 
automation is unavailable but costly equipment such as a cryostat machine 
for frozen sectioning, deep freezers at -80°C to store these sections until 
staining and an ultraviolet light attachment for light microscopy is required. 
Two biopsies are necessary to perform routine H&E staining as well as direct 
immunofluorescence because the later cannot be performed on paraffin 
embedded tissue. Immunofluorescence does not permitt the examination of 
cytological detail as well as histomorphology and results are often equivocal 
due to poor resolution.(12, 16, 18-20) Furthermore, fluorescence decays with 
time and with exposure to light therefore slides cannot be reviewed at a later 
stage.(12, 20) Processing of specimens from known human 
immunodeficiency virus (HIV)-reactive patients is avoided in some 
laboratories due to the risk of accidental transmission of HIV and hepatitis B 
whilst handling fresh infectious tissues under sharp sectioning blades. In 
developing countries with limited resources, some of which have the highest 
burdens of HIV and hepatitis B, this may be impractical thus further 
emphasising the need for the development of other easily accessabile 
confirmatory techniques. 
Indirect immunofluorescence of blister fluid, serum or urine is another 
immunopathological technique used to confirm and monitor bullous 
pemphigoid. Circulating IgG or C3 bind in a linear pattern at the basement 
membrane zone of squamous epithelia substrates such as normal skin or 
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monkey oesophagus (Figure 7).(2, 3, 7, 11) Although this test is sensitive 
and highly specific (21), it is only performed in a few centres globally.  
Other less commonly used immune-based tests: 
Additional specialised diagnostic techniques for bullous pemphigoid, used 
predominantly for research purposes, include the enzyme-linked 
immunosorbent assay (ELISA) for serum levels of antibodies to BP180 and 
BP230. The NC16A domain, a pathogenic epitope of the BP180 antigen, is 
also used to correlate disease activity with antibody titres for selected cases 
only.(2) Immunoblot and immunoprecipitation are also highly specific 
research tools used to demonstrate the reactivity of IgG from patient sera 
with 180kDa and 230kDa bullous pemphigoid antigens (BP180 and BP230 
respectively).(3, 22)  
Lastly, laser scanning confocal microscopy allows precise localisation of in 
vivo-bound IgG and has been used as an extremely specialised, rapid 
method for differentiating bullous pemphigoid from EBA and cicatricial 
pemphigoid.(23) In vivo-bound IgG is localised on the epidermal side of 
laminin 5 and co-localised with B4 integrin in bullous pemphigoid, whereas in 
EBA, the IgG is present on the dermal side of collagen IV. In cicatricial 
pemphigoid, IgG is bound between laminin 5 and type IV collagen.(23)  
A prospective study undertaken by Chan et al compared these tests in 23 
cases of bullous pemphigoid diagnosed clinically. They found 91% (21/23) 
demonstrated linear deposits of IgG and C3 along the dermo-epidermal 
junction on direct immunofluorescence whereas 96% (22/23) were positive 
on serum indirect immunofluorescence, all of which bound to the epidermal 
side of the cleft on salt-split skin. The BP180 NC16A antibody was also 
detected in 96% (22/23) using the ELISA technique but the immunoblot was 
superior with positive reactivity to BP 180 and/or BP230 in 100% (23/23). 
However, it was described as being technically very demanding.(24)  
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1.3 Immunohistochemistry 
1.3.1 Techniques in Immunohistochemistry 
Immunohistochemistry is a histopathological technique, not routinely 
performed in bullous pemphigoid, whereby specific antibodies are used to 
localise desired antigens within fresh or frozen tissue specimens.(19) 
Significant advances in the use of immunohistochemistry were made in the 
early 1990’s and in 1991 a breakthrough made it possible to perform antigen 
retrieval in formalin-fixed, paraffin-embedded tissues as well.(25) This 
sparked new insights and interest in the field and broadened the test’s 
capabilities.(25) An increase of publications in this regard was prompted; 
including that regarding the use of collagen IV immunohistochemistry. The 
technique may be performed manually (using precise laboratory protocols) or 
in automated platforms that have the advantage of enhanced quality and 
reproducibility.(16) Monoclonal or polyclonal antibodies can be used but 
differ in their binding affinities and specificities such that monoclonal 
antibodies, which react with only one epitope, are highly specific but less 
sensitive versus polyclonal antibodies that react with multiple epitopes of a 
single antigen becoming less specific but highly sensitive.(19, 26)  
The initial and traditional direct immunohistochemistry technique involves the 
reaction of labeled antibodies directly with tissue antigen. Indirect techniques 
include the two-step technique whereby a labeled secondary antibody is 
directed against an unlabeled primary antibody that is bound to the relevant 
antigen. The three-step indirect technique, also called the labeled 
streptavidin-biotin method, is another indirect method involving the 
attachment of an unconjugated primary antibody to the tissue antigen 
creating an antigen-antibody complex. Secondly, a biotinylated secondary 
antibody is directed against the primary antibody followed lastly by enzyme-
labeled streptavidin or a complex of enzyme-labeled biotin and streptavidin 
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that is bound to the secondary antibody. The enzyme used may be 
horseradish peroxidase or alkaline phosphatase. In addition, the relevant 
chromogens are used for detection, such as diaminobenzidine or 3-amino-9 
ethylcarbazole used in the peroxidase method or indole reagents, naphthol 
fast red or nitro blue tetrazolium/ 5-bromo-4-chloro-3-indolyl-phosphate 
(NBT/BCIP) chromogens used in the alkaline phosphatase-streptavidin 
method.(16, 27)
Although the streptavidin-biotin method has been used widely, the presence 
of endogenous biotin within specimens may result in unwanted background 
staining. Other newer and improved polymer detection systems that are 
quicker, reliable and reproducible with greater sensitivity have been 
developed including the Enhanced Polymer One Step technique. This 
popular method involves the attachment of multiple enzyme molecules and 
specific primary antibodies to a dextran backbone processed via manual or 
automated immunohistochemistry.(16, 27)
False positive results within immunohistochemistry may be related to 1) 
chromogen entrapment due to inadequate rinsing, prolonged chromogen 
time as well as chatter, tears, folds, wrinkles and poor adhesion of sections 
to slides; 2) precipitation of chromogen which may be prevented by adequate 
filtering and 3) contaminants acquired during handling water baths, tissue 
sections and slides with ungloved hands. In contrast, false negative results 
can occur due to tissue processing errors such as 1) incomplete 
paraffinisation resulting in suboptimal staining because of incomplete tissue 
penetration by antibodies; 2) over-digestion of tissue sections by proteolytic 
enzymes that destroy tissue antigens; 3) incorrect temperature of reagents; 
4) expired antibodies; 5) inappropriate dilutions and 6) suboptimal storage of
antibodies. Nonetheless, errors such as these may be easily avoided by
adhering to precise laboratory protocols when performing
immunohistochemistry manually as well as on automated platforms.(16)
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1.3.2  Collagen IV Immunohistochemistry and autoimmune bullous 
disorders  
Collagen IV immunohistochemistry may be performed in the diagnosis of 
bullous pemphigoid. Autoantibodies target hemidesmosomal antigens 
forming a cleft above the lamina densa where collagen IV, part of the normal 
structure of the basement membrane zone, is located. In this way, 
immunostaining of collagen IV should be detected on the floor of 
subepidermal blisters in bullous pemphigoid (Figure 8). This is supported by 
Pardo et al who reported that immunohistochemistry is a reliable, fast and 
readily available laboratory tool to determine the level of collagen IV within a 
subepidermal blister.(18)  
The usefulness of collagen IV immunohistochemistry has been described in 
dogs to confirm the diagnosis of EBA but it is also used in humans.(18, 28)
EBA is an autoimmune blistering condition characterized by autoantibodies 
against collagen VII in the sublamina densa of the dermo-epidermal junction 
(below the lamina densa where collagen IV is located) resulting in a cleft at 
this level. Therefore, collagen IV immunostaining will be detected on the roof 
of subepidermal blisters formed in EBA. 
Collagen IV immunohistochemistry is a rapid simple tool that utilises readily 
available reagents and can be performed locally in most pathology 
laboratories.(18) Apart from bullous pemphigoid, porphyria cutanea tarda, 
dermatitis herpetiformis and adult linear IgA bullous dermatosis may also 
present with subepidermal blisters which demonstrate collagen IV 
immunostaining at the floor.(18, 29, 30) However, other defining histological 
features such as cell-poor blisters, festooning and hyalinised vessels in 
porphyria cutanea tarda can differentiate these subepidermal blisters from 
those of bullous pemphigoid. In addition, investigations such as urinary 
porphyrins are diagnostic in porphyria and cutaneous features such as 
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scarring and photosensitivity are rarely confused with bullous pemphigoid. 
Patients with dermatitis herpetiformis may also have features of gluten-
intolerance that will distinguish it from other autoimmune bullous dermatoses 
and linear IgA demonstrates predominantly neutrophil rich blisters on 
histology. 
2. SYSTEMATIC LITERATURE REVEIW
2.1 Objective 
To identify and review studies that have investigated the use of collagen IV 
immunohistochemistry alone or compared with immunofluorescence in the 
diagnosis of bullous pemphigoid.  
2.2 Literature search strategy 
Searches were conducted in five databases to identify recent publications 
until December 2016: Medline via PubMed, Scopus, Academic Search 
Premier, Africa-Wide Information via EBSCO host and Google Scholar. The 
following search terms were used in various combinations: bullous 
dermatoses, vesicobullous skin diseases, bullous pemphigoid, 
immunohistochemistry and collagen IV (Table 1). Searches were limited to 
English articles concerning humans within the field of medicine and no filter 
was set regarding publication-date. Abstracts of identified documents were 
read and the full text of relevant documents were retrieved for inclusion in the 
review. Reference lists of retrieved documents were also searched to identify 
additional publications. All articles regarding the use of collagen IV 
immunohistochemistry in patients with bullous pemphigoid were included. A 
summary of the database searches is set out below.  
26	
2.3 Results of literature search 
Two diagnostic studies were found that investigated the use of collagen IV 
immnohistochemistry in a total of 33 participants with bullous pemphigoid. All 
cases stained the floor of a subepidermal blister (Table 2). Of these, 25/25 
cases were in agreement with direct immunofluorecence and 7/8 cases with 
indirect immunofluorescence, which were used as reference standard 
investigtions. 
In the first study, Pardo et al performed a prospective study of 25 cases of 
bullous pemphigoid, 12 cases of porphyria cutanea tarda and three cases of 
dermatitis herpetiformis, which were all confirmed on direct 
immunofluorescence. Five clinically established longstanding cases of EBA 
that had been confirmed by unspecified investigations at the time of 
diagnosis were also included. Sections of all cases were stained with H&E to 
confirm the presence of subepidermal blisters. Thereafter, the indirect avidin-
biotin-peroxidase immunohistochemical technique was performed using 
polyclonal rabbit antibodies against collagen IV (primary antibody) and goat 
anti-rabbit IgG (secondary antibody) on deparaffinised tissue sections that 
had been formaldehyde-fixed and paraffin-embedded prior to processing.(18) 
Positive collagen IV immunostaining was demonstrated on the floor of 100% 
of the bullous pemphigoid cases (25/25), the porphyria cutanea tarda cases 
(12/12) and the dermatitis herpetiformis cases (3/3). In all of the EBA cases 
(5/5), collagen IV stained the roof of the subepidermal blisters.(18) This small 
study suggests that collagen IV immunostaining is not only consistent with 
direct immunofluorescence but reliably distinguishes between autoimmune 
blistering disorders based on target antigen location on either the floor or roof 
of the blister. 
The second study, undertaken by Bowszyc-Dmochowska et al prospectively, 
tested eight cases of bullous pemphigoid. Two cases of EBA and five 
controls (including two cases of dermatitis herpetiformis, two cases of bullous 
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lichen sclerosis and one case of localised recessive dystrophic epidermolysis 
bullosa inversa) were also included. All cases were confirmed with salt-split 
skin indirect immunofluorescence on human skin and immunoblot. Tissues 
were formalin-fixed and paraffin-embedded before processing and routine 
H&E staining was performed on each section. The avidin-biotin 
immunohistochemical technique was also performed but pre-diluted mouse 
monoclonal antibodies and anti-mouse biotinylated antibodies were utilised. 
In all cases of bullous pemphigoid (8/8), collagen IV stained positively on the 
floor of the subepidermal blisters. All cases were also positive on the 
immunoblot but the salt split skin indirect immunoflourence demonstrated 
fluorescence on the epidermal side of the split in 86% (7/8) and on both the 
epidermal and dermal side of the split in one case (1/8). In the EBA cases, 
collagen IV stained the roof of the blister clearly with lighter staining on the 
floor in one and the other stained equivocally. Two of the control cases, 
namely dermatitis herpetiformis, stained at the base of the blisters whereas 
the other control cases stained positively on the roof.(29)  
3. DISCUSSION
The results of both studies confirm that the location of collagen IV at the 
basement membrane zone in relation to a subepidermal blister can be 
identified in routinely processed tissue i.e. formaldehyde-fixed and paraffin-
embedded. They are also in keeping with the theoretical background of 
subepidermal blister formation in bullous pemphigoid. Overall, collagen IV 
demonstrates good accordance with the reference standards thus 
highlighting the potential role of collagen IV immunohistochemistry as a 
sensitive test in the confirmation of clinically suspicious bullous pemphigoid.  
Test Accuracy: 
Immunofluorescence (on salt-split skin) and immunoblot, both highly reliable 
techniques in the diagnosis of autoimmune bullous dermatoses (2, 3, 7, 12, 
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15, 22), were utilised as reference standards. The collagen IV results of all 
cases of bullous pemphigoid, porphyria cutanea tarda, dermatitis 
herpetiformis, bullous lichen sclerosis and localised recessive dystrophic 
epidermolysis bullosa inversa demonstrated positive agreement with these 
tests thus verifying collagen IV as an accurate test. One exception was a 
case of bullous pemphigoid, where IgG antibodies bound to both epidermal 
and dermal sides of the split on indirect immunofluorescence, which is out of 
keeping with the theoretical background. However, the same case was 
confirmed on immunoblot thus the unexpected result might represent the 
presence of the rarely described BP200 dermal-binding antigen (31) or an 
artifact due to tissue handling and processing errors.  
Test Validity: 
In the first study, non-immune rabbit serum was used in antibody control 
sections and collagen IV detected around blood vessels and adnexae served 
as an internal control. The second study did not report on antibody and 
internal controls but utilised clinical control cases. Although not specified, the 
additional cases in the first study also served as clinical controls against 
bullous pemphigoid. The results of all positive controls in both studies were in 
keeping with the theoretical expectations of subepidermal blister formation in 
each disorder and they were in agreement with the reference standards used 
thus helping to validate collagen IV. 
Bias: 
The number of investigators and whether or not they were blinded was not 
reported in either study. This is important as the results of 
immunofluorescence and immunohistochemistry techniques are interpreter 
dependent and will influence observer bias. In this way, the accuracy of the 
index test, collagen IV, may have been overestimated. However, in the first 
study, serial dilutions of the antiserum were performed to determine optimal 
antibody concentrations and hydrogen peroxidase was utilised to reduce 
background staining that commonly occurs in the avidin-biotin method, as 
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previously described. The second study utilised pre-diluted commercial 
antibodies and sections were treated with alpha-chymotrypsin to enhance the 
reactivity of collagen IV at the basement membrane zone. These techniques 
might have helped to reduce the chance of observer bias by ensuring 
adequate staining quality that would make interpretation of the 
immunostaining easier.  
Sensitivity and Specificity: 
Both studies, although small, included patients with different autoimmune 
bullous dermatoses. No false positive or false negative collagen IV results 
were detected in either study in the bullous pemphigoid group. This is in line 
with good test sensitivity and specificity but larger sample sizes including 
disease free controls are required to confirm this observation.  
Positive test agreement of all cases of bullous pemphigoid with the reference 
standards suggests that collagen IV on the floor of a subepidermal blister is a 
sensitive test. However, because more than one condition may demonstrate 
collagen IV on the floor, clinical-pathologic correlation is still crucial in order 
to confirm the results. The findings of both studies also suggest that collagen 
IV staining the roof of a subepidermal blister may be used as a specific test 
to exclude bullous pemphigoid, as none of these cases presented with 
collagen IV on the roof.  
Research gaps: 
Both studies reported similar results in the bullous pemphigoid groups, but 
only include a total of 33 patients. Prospective studies are required to better 
regulate sample collection and processing in order to avoid artifacts that may 
influence test results. Furthermore, studies with more than one blinded 
investigator would provide more accurate results by avoiding observer bias. 
Ideally, larger sample sizes of confirmed cases of bullous pemphigoid and 
disease-free controls are required to verify test reliability and reproducibility 
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as well as to calculate test sensitivity and specificity. In addition to this, 
positive and negative predictive values might also be calculated. These 
values will provide a measure of the proportion of people with a positive test 
who have the condition, and vice versa, in relation to test accuracy and the 
prevalence of bullous pemphigoid.  
4. CONCLUSION AND RECOMMENDATIONS
We found two published studies (reporting only 33 patients) comparing 
collagen IV immunohistochemistry and immunofluorescence in the diagnosis 
of bullous pemphigoid. In spite of promising results from these two small 
studies from 1990 and 1997, no other work has been published on the 
subject. In our clinical practice collagen IV is often used in addition to direct 
immunofluorescence in the diagnosis of bullous pemphigoid. The current 
study (Chapter 2 of this thesis), entitled “The use of collagen IV 
immunohistochemistry in the diagnosis of bullous pemphigoid”, includes a 
larger than published patient number and it will be the first to our knowledge 
to investigate collagen IV test agreement with direct immunofluorescence in 
the diagnosis of bullous pemphigoid at a hospital in Africa and the rest of the 
world since the late 1990’s. The results will provide insight into the value of 
collagen IV immunohistochemistry, which is more readily available than 
direct immunofluorescence, in the diagnosis of bullous pemphigoid.  
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6. TABLES
Table 1 
Literature Search Stratergy 
Database 
searched 
Search Terms Limits Results Used 
Medline/PubMed (immunohistochemical 
method) and (bullous 
dermatoses) MeSH terms 
(methods, skin, diseases, 
vesicobullous, 
vesicobullous skin 
diseases) 
English 112 1 
Medline/PubMed (immunohistochemical 
method) and (bullous 
pemphigoid) 
MeSH terms (Methods) 
English 29 2 
Medline/PubMed (collagen IV) and (bullous 
pemphigoid) 
English 141 1 
Scopus (immunohistochemical 
method) and (bullous 
dermatoses) 
English 5 0 
Scopus (immunohistochemical 
method) and (bullous 
pemphigoid) 
English 37 2 
Scopus (collagen IV) and (bullous 
pemphigoid) 
English, 
Humans, 
Medicine, 
146 2 
Academic Search 
Premier 
(immunohistochem*) and 
(bullous*) 
English 163 1 
Academic Search 
Premier 
(immunohistochem*) and 
(bullous pemphigoid) 
English 91 1 
Africa-Wide 
Information/ 
EBSCO host 
(immunohistochem*) and 
(bullous*) 
English 5 0 
Africa-Wide 
Information/ 
EBSCO host 
(immunohistochem*) and 
(bullous pemphigoid) 
English 0 0 
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Table 2 
Literature Search Results 
Author, 
Year  & 
Country 
Investigation & 
Participant Number 
Outcome 
Pardo et al 
1990 
USA(18) 
Collagen IV 
25 cases 
Direct 
immunofluorescence 
25 cases 
Positive on floor of subepidermal blister in: 
25/25 cases of bullous pemphigoid, 
12/12 cases of porphyria cutanea tarda,  
3/3 cases of dermatitis herpetiformis 
Positive on roof of subepidermal blister in:  
5/5 cases of EBA 
Positive in 25/25 cases 
Bowszyc-
Dmochowska 
1997 
Poland(29) 
Collagen IV 
8 cases 
Direct 
immunofluorescence 
8 cases 
Positive on floor of subepidermal blister in: 
8/8 cases of bullous pemphigoid and 
1/3 cases of EBA 
Positive on roof of subepidermal blister in:  
1/3 cases of EBA and 
Equivocal in 1/3 cases of EBA  
Positive in 7/8 cases 
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7. FIGURES
Figure 1: Tense cutaneous blisters and erosions 
with haemorrhagic crusts on an erythematous 
base in a patient with bullous pemphigoid 
Figure 2: Tense cutaneous blisters overlying 
urticarial plaques in a patient with bullous 
pemphigoid 
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Figure 3: Haematoxylin & eosin 100x 
objective magnification: The section 
shows a cell rich subepidermal blister 
containing inflammatory cells
Figure 4: Haematoxylin & eosin 400x 
objective magnification: The section 
shows a cell rich subepidermal blister 
containing numerous eosinophils
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Figure 5: 100x objective magnification 
of IgG direct immunofluorescence 
demonstrating 3+ linear staining at the 
dermo-epidermal junction 
Figure 6: 100x objective magnification: 
C3 direct immunofluorescence 
demonstrating 3+ linear staining at the 
dermo-epidermal junction 
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 (32) 
Figure 8: 100x objective 
magnification: Collagen IV 
immunohistochemistry stain showing 
positive staining at the floor of the 
blister cavity. An overlying 
subepidermal blister is noted. 
Figure 7: Indirect immunofluorescence 
performed on salt-split normal human skin substrate 
with the serum from a patient with bullous 
pemphigoid demonstrating circulating IgG 
autoantibodies binding to the epidermal side of the 
dermo-epidermal junction 
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Statements (70 words): 
• What is known about topic?
Immunofluorescence is the most relied on investigation in the diagnosis of
bullous pemphigoid but it requires specialised equipment thus limiting its use
in resource-limited settings.
• What does this study add?
This study demonstrates the potential use of collagen IV
immunohistochemistry as a simple, reliable and accessible alternative to
direct immunofluorescence in the diagnosis of bullous pemphigoid.
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Abstract
Autoimmune bullous dermatoses present with overlapping clinical features 
that require histopathological correlation. Immunofluorescence is the most 
reliable but requires expensive equipment and expertise. Collagen IV 
immunohistochemistry, which is performed on formalin fixed tissue, has been 
compared to immunofluorescence in the diagnosis of bullous dermatoses. A 
systematic search of five databases identified two small studies comprising 
33 participants which showed good agreement between immunofluorescence 
and collagen IV in bullous pemphigoid. No other study since 1997 has 
confirmed of refuted these findings. 
Methods 
A retrospective study of all patients diagnosed with bullous pemphigoid over 
12 years within a tertiary dermatology department was performed. Patient 
records with both collagen IV and direct immunofluorescence results were 
selected and the positive percentage agreement was calculated. 
Results 
Collagen IV was positive in 96% (79/82) and direct immunofluorescence in 
85% (72/82) of patients with clinical bullous pemphigoid. A positive 
percentage agreement of 80.5% suggests a strong test accordance. 
Limitations 
The retrospective design and lack of controls without bullous pemphigoid 
made it impossible to calculate sensitivity and specificity or to confirm test 
agreement with the kappa statistic. 
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Conclusion 
This is the largest study, comparing direct immunofluorescence and collagen 
IV in the same patients diagnosed with bullous pemphigoid. Collagen IV 
immunohistochemistry can be performed on one biopsy also used for routine 
histology. It is a simple, widely available tool that has accordance with and 
may be more sensitive than direct immunofluorescence in the diagnosis of 
bullous pemphigoid. Confirmation in larger controlled studies is essential as 
collagen IV immunohistochemistry is accessible in resource-limited countries. 
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Introduction 
Bullous pemphigoid is the most common acquired autoimmune blistering 
dermatosis of the skin in Western Europe (1) and globally. It is characterised 
by large, tense cutaneous bullae which commonly affect the elderly but may 
present in children.(2) Cutaneous blistering diseases with differing 
aetiologies, pathogeneses and prognoses including other autoimmune and 
genetic bullous diseases may have clinical features which overlap with that of 
bullous pemphigoid. This might be due to the severity and stage of disease 
at the time of examination and the effect of previous treatments used.(3-5)
Therefore, in order to confirm the diagnosis, histopathological correlation is 
required.(2) Routinely, immunofluorescence is considered most reliable, but 
requires specialised equipment and expertise. Thus it is not widely 
accessible particularly in poor countries.  
A systematic literature search of five databases for all studies written in 
English that describe the use of collagen IV immunohistochemistry and those 
comparing it with immunofluorescence in the diagnosis of bullous 
pemphigoid identified only small two studies.	All reported 33 (100%) bullous 
pemphigoid cases demonstrated collagen IV on the floor of a subepidermal 
blister. Of these, 25/25 cases concurred with direct immunofluorescence (6) 
and 7/8 with indirect immunofluorescence (7) which were used as reference 
standard investigations. It is noteworthy that in spite of good agreement 
between immunofluorescence and collagen IV immunohistochemistry, no 
data confirming or refuting this finding in larger studies has been published 
since 1997. In our clinical practice collagen IV is often used in addition to 
direct immunofluorescence in the diagnosis of bullous pemphigoid. 
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Methods 
A retrospective record analysis was performed of all inpatients and 
outpatients with a clinical diagnosis of bullous pemphigoid between February 
2003 and May 2015 within a dermatology department at a specialist referral 
hospital in South Africa.  
Participants with the following were included: 1) Tense cutaneous blisters 
with or without an erythematous base and with or without pruritus; 2) a 
subepidermal blister with associated eosinophils on histology; 3) collagen IV 
immunohistochemistry staining from biopsy of a blister and 4) direct 
immunofluorescence performed on perilesional skin.   
Commercially available Ventana polyclonal mouse and polyclonal goat 
primary antibodies were used in the collagen IV immunohistochemistry and 
direct immunofluorescence techniques respectively. Both methods were 
routinely performed on the Ventana Benchmark and Benchmark Ultra 
automated platforms. Collagen IV staining the floor of a subepidermal blister 
was considered positive as demonstrated (fig. 1). Direct immunofluorescence 
of perilesional skin biopsies reported as demonstrating immunoglobulin G 
(IgG) (fig. 2) and/or complement 3 (C3) at the basement membrane zone 
fluorescing in a linear pattern was accepted as a positive test. The strength 
of fluorescence was graded 1+ to 3+, where 1+ is weak and 3+ is strong. 
Negative direct immunofluorescence was defined as no fluorescence, 
detection of IgA and/or IgM only at the basement membrane zone or 
equivocal findings. The positive percentage agreement between collagen IV 
immunohistochemistry and direct immunofluorescence was analysed.  
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Results 
In total, 82 participants were included in the study; 77% (63/82) were female, 
27% (22/82) were male. The mean age was 69 years old.  
Collagen IV immunohistochemistry was positive in 96% (79/82) of cases 
(table 1) and direct immunofluorescence was positive in 84% (69/82) of 
which IgG and C3 stained positively in 64% (44/69), 9% (6/69) for IgG only 
and 15% (10/69) for C3 only (fig 3). A positive percentage agreement of 
80.5% suggests a strongly positive test accordance.  
Discussion 
Our results reflect that collagen IV immunohistochemistry has good 
accordance with direct immunofluorescence in the diagnosis of bullous 
pemphigoid. Only three cases in our study did not detect collagen IV at the 
base of a subepidermal blister. No blister was present in all of these sections 
thus the test could not be interpreted. Therefore, with clinical-pathologic 
correlation, collagen IV performed on a blister is a useful alternative when 
direct immunofluorescence is unavailable. 
Immunohistochemistry is a rapid and simple tool that utilises readily available 
reagents and can be performed locally in most pathology laboratories.(6)
However, there have been surprisingly few studies regarding the use of 
collagen IV. We found two studies of 25 and eight confirmed cases of bullous 
pemphigoid respectively that demonstrated positive collagen IV staining the 
floor of all subepidermal blisters. All cases in the former study were in 
agreement with direct immunofluorescence and 7/8 cases in the later with 
indirect immunofluorescence.(6, 7) Both studies confirm the validity of this 
test and verify that collagen IV can be used to determine the level of a 
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subepidermal blister at the basement membrane zone on routinely formalin-
fixed and paraffin-embedded tissues. Thus only one biopsy is required for 
routine histology and immunohistochemistry. Furthermore, good accordance 
with immunofluorescence and the lack of false positives in these studies is in 
keeping with good test sensitivity. The results also suggested that bullous 
pemphigoid can be excluded if collagen IV stains the roof of a subepidermal 
blister. Overall, these studies are limited by their retrospective nature, small 
sample sizes and observer bias that might have lead to overestimation of test 
accuracy, but our study findings are in support of their outcomes.  
Direct immunofluorescence has long been considered the most reliable 
investigation in the diagnosis of bullous pemphigoid.(1, 5, 8-10) One study 
was found that investigated the use of direct immunofluorescence in 227 
participants with bullous pemphigoid confirmed by any two investigations 
including histopathology, indirect immunofluorescence and enzyme-linked 
immunosorbent assay against 448 disease free-controls. They calculated a 
sensitivity and specificity of 90.8% (CI: 86.2%-94.2%) and 98% (CI: 96.2%-
99.1%) respectively. This was a large study that was only limited by its 
retrospective nature.(11)  
Despite the efficacy of direct immunofluorescence, contrary to 
immunohistochemistry, it is not as readily available and is more 
sophisticated. Specialised equipment such as a cryostat machine for frozen 
sectioning, deep freezers to store sections until staining and an ultraviolet 
light attachment for light microscopy are required. Two biopsies, one of a 
blister for formalin-fixation and paraffin-embedding to perform routine 
histology and another fresh perilesional biopsy for direct 
immunofluorescence are required. Skilled pathologists to perform and 
interpret this test are vital as the site, strength and pattern of fluorescence 
varies amongst several autoimmune bullous dermatoses. Furthermore, 
fluorescence decays with time and on exposure to light whereas 
immunohistochemistry is permanent.(5) Another disadvantage is the 
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increased risk of human immunodeficiency virus and hepatitis transmission, 
diseases which place a high burden on poor and developing countries, 
because of handling fresh tissues on sectioning blades in this technique.  
Limitations 
Due to the retrospective nature of this study, clinical information was 
dependent on accurate record keeping by doctors and sampling error as well 
as biopsy technique could not be accounted for. The sample size, which is 
larger than preceding studies, but still too small together with the lack of 
clinical controls, made it impossible to calculate sensitivity, specificity and the 
kappa statistic.  
Conclusion and recommendations 
Collagen IV immunohistochemistry is a simple, widely available test that has 
good accordance with direct immunofluorescence. Through clinical and 
histomorphological correlation, it may be a useful confirmatory tool in 
resource-limited settings where immunofluorecence is not possible. 
Furthermore, collagen IV is not only more accessible, but it can be performed 
on the same biopsy used for routine histology thus further reducing the cost 
of diagnostic confirmation. However, larger controlled studies are warranted. 
Conflict of interest 
None to declare 
49	
References 
1. Kirtschig	G,	Middleton	P,	Bennett	C,	Murrell	DF,	Wojnarowska	F,Khumalo	NP.	Interventions	for	bullous	pemphigoid.	Cochrane	Database	SystRev.	2010(10):CD002292.2. Feliciani	C,	Joly	P,	Jonkman	MF,	Zambruno	G,	Zillikens	D,	Ioannides	D,	etal.	Management	of	bullous	pemphigoid:	the	European	Dermatology	Forumconsensus	in	collaboration	with	the	European	Academy	of	Dermatology	andVenereology.	Br	J	Dermatol.	2015;172(4):867-77.3. Arundhathi	S,	Ragunatha	S,	Mahadeva	KC.	A	Cross-sectional	Study	ofClinical,	Histopathological	and	Direct	Immunofluorescence	Spectrum	ofVesiculobullous	Disorders.	Journal	of	Clinical	and	Diagnostic	Research.2013;7(12):2788-92.4. Baum	S,	Zafrir	Y,	Barzilai	A.	Detection	of	autoantibodies	in	autoimmunebullous	skin	diseases:	Can	we	do	better?	Israel	Medical	Association	Journal.2014;16:244-5.5. Chhabra	S,	Minz	RW,	Saikia	B.	Immunofluorescence	in	dermatology.Indian	Journal	of	Dermatology,	Venereology,	and	Leprology.	2012;78(6):677-90.6. Pardo	RJ,	Penneys	NS.	Location	of	basement	membrane	type	IV	collagenbeneanth	subepidermal	bullous	diseases.	Journal	of	Cutaneous	Pathology.1990;28(1):11-6.7. Bowszyc-Dmochowska	M,	Hashimoto	T,	Dmochowska	M,	Nishikawa	T.Evaluation	of	an	Avidin-Biotin-Peroxidase	Method	with	a	Monoclonal	Antibodyto	Type	IV	Collagen	in	the	Differential	Diagnosis	of	Bullous	Pemphigoid	andEpidermolysis	Bullosa	Acquisita.	The	Journal	of	Dermatology.	1997;24(4):217-22.8. Venning	VA,	Taghipour	K,	Mohd	Mustapa	MF,	Highet	AS,	Kirtschig	G.British	Association	of	Dermatologists'	guidelines	for	the	management	of	bullouspemphigoid	2012.	Br	J	Dermatol.	2012;167(6):1200-14.9. Wojnarowska	F,	Kirtschig	G,	Highet	AS,	Venning	VA,	Khumalo	NP.Guidelines	for	the	management	of	bullous	pemphigoid.	British	Journal	ofDermatology.	2002;147(2):214-21.10. Buch	AC,	Kumar	H,	Panicker	N,	Misal	S,	Sharma	Y,	Gore	CR.	A	Cross-sectional	Study	of	Direct	Immunofluorescence	in	the	Diagnosis	ofImmunobullous	Dermatoses.	Indian	J	Dermatol.	2014;59(4):364-8.11. Sárdy	M,	Kostaki	D,	Varga	R,	Peris	K,	Ruzicka	T.	Comparative	study	ofdirect	and	indirect	immunofluorescence	and	of	bullous	pemphigoid	180	and230	enzyme-linked	immunosorbent	assays	for	diagnosis	of	bullous	pemphigoid.	Journal	of	the	American	Academy	of	Dermatology.	2013;69(5):748-53.
50	
Table 
Table 1 
Collagen	IV	
Positive	 Negative	 Total	
Direct	Immunofluorescence	 Positive	 66	 3	 69	
Negative	 13	 0	 13	
Total	 79	 3	 82	
51	
Figures 
Figure 1: 100x objective magnification: Collagen IV 
immunohistochemistry stain showing positive staining at the 
base of the blister cavity. An overlying subepidermal blister is 
noted. 
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Figure 2: 100x objective magnification: C3 direct immunofluorescence 
demonstrating 3+ linear staining at the dermo-epidermal 
junction 
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Figure 3 
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Author Consent Form [req] 
Online Submission 
Patient Consent Form 
CONSORT Checklist [req for RCTs] 
STROBE Checklists (Cohort, Case-control, Cross-sectional) [req for 
observational studies] 
Open Access Order Form 
Peer-review Process Map 
Contact the Editorial Office 
 
1. ABOUT BJD 
 
Aims & Scope 
 
The British Journal of Dermatology (BJD) strives to publish the highest 
quality dermatological research. In so doing, the journal aims to advance 
understanding, management and treatment of skin disease and improve 
patient outcomes. 
 
BJD invites submissions under a broad scope of topics relevant to clinical 
and experimental research and publishes original articles, reviews, case 
reports and items of correspondence. The article categories within the journal 
are: cutaneous biology; clinical and laboratory investigations; contact 
dermatitis & allergy; dermatological surgery & lasers; dermatopathology; 
epidemiology & health services research; paediatric dermatology; 
photobiology; and therapeutics. 
 
BJD is an official organ of the British Association of Dermatologists but 
attracts contributions from all countries in which sound research is carried 
out, and its circulation is equally international. The overriding criteria for 
publication are scientific merit, originality and interest to a multidisciplinary 
audience. 
 
Journal content and further information—including author guidelines and 
submission details—can be found online at www.brjdermatol.org. The 2010 
impact factor is 4.353. 
 
Mission & Values 
 
Founded in 1888, BJD has evolved into one of the world’s leading general 
dermatology journals. The BJD brand is underpinned by the provision of 
trusted information. From this solid foundation, the journal aims to serve the 
needs of its multiple stakeholders. 
 
• For authors, BJD aims to provide a quick, dependable and fair peer-review 
service focused on improving the quality of accepted manuscripts. 
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Article production should be quick and accurate and free of any 
charges. 
• BJD recognises the invaluable role of reviewers in safeguarding the 
integrity of content and aims to acknowledge fully their contribution. 
• For readers, BJD aims to deliver the highest quality clinical and 
experimental research spanning the continuum of dermatological 
disciplines. Content should be readily discoverable and user-friendly. 
Online innovation should add value to content, promote understanding 
and facilitate clinical decision-making. 
• For subscribers, BJD aims to offer flexible purchasing options—from 
individual article downloads to multi-year, multi-site licences—at 
reasonable prices. 
• For sponsors, BJD aims to offer ethical marketing solutions which yield 
measurable returns on investment. 
 
2. MANUSCRIPT CATEGORIES 
 
BJD invites the following types of submission: 
 
Review articles 
 
The Journal aims to publish concise, high-quality review articles of recent 
advances in laboratory or clinical research. Review articles may be solicited 
by the Editor or may be submitted by authors for publication subject to peer 
review. Review articles must include an unstructured abstract (maximum 250 
words), and should not exceed 3000 words of body text. Use of illustrations 
and figures is encouraged. Review articles must include bulleted statements 
(maximum 70 words) in answer to the following questions: what's already 
known about this topic?; what does this study add? 
 
Original articles 
 
Original articles are the Journal’s primary mode of communication. Original 
articles must include a structured abstract (maximum 250 words), and should 
not exceed 3000 words of body text. Original articles must include bulleted 
statements (maximum 70 words) in answer to the following questions: what's 
already known about this topic?; what does this study add? 
Manuscripts reporting randomised controlled trials (RCTs) must follow the 
CONSORT statement. RCTs will not be considered by BJD without 
submission of a completed CONSORT checklist. Manuscripts reporting 
observational studies must follow the STROBE guidelines. Observational 
studies will not be considered by BJD without submission of the relevant 
STROBE checklist. 
Submissions reporting industry-sponsored clinical research are welcomed. 
The British Journal of Dermatology recommends all authors take account of 
the following guidelines when preparing their manuscript: Ten 
Recommendations for Closing the Credibility Gap in Reporting Industry-
Sponsored Clinical Research. 
For purposes of presentation only, accepted original articles are divided into 
the following sections: 
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Cutaneous biology 
Clinical and laboratory investigations 
Contact dermatitis and allergy 
Dermatological surgery and lasers 
Dermatopathology 
Epidemiology and health services research 
Genetics [1] 
Paediatric dermatology 
Photobiology 
Therapeutics 
 
Perspectives 
 
The BJD welcomes submissions to the perspectives section covering a wide 
variety of topics relevant to contemporary dermatology healthcare and 
research. Such pieces can be opinion essays, which are similar in style to 
editorials, but are not tied to a particular article and clearly represent the 
views and opinions of the author(s) not the BJD. Perspectives articles can 
also address a range of social aspects of medicine and healthcare that are 
relevant to the practice of dermatology throughout the world. Perspectives 
should be concise, accessible, carefully crafted pieces; they are limited to 
1,500-2000 words. Perspectives can include one figure or table and a 
maximum of 5-10 references. Perspectives are usually invited articles, but 
may also be submitted as unsolicited articles as long as they conform to the 
above instructions to authors. 
 
Case reports 
 
BJD includes only case reports of novel and extraordinary significance. Case 
reports must include an unstructured abstract and should not exceed 1200 
words of body text with up to 15 references and 4 tables or figures. Case 
reports must include bulleted statements (maximum 70 words) in answer to 
the following questions: what's already known about this topic?; what does 
this study add? 
 
Correspondence 
 
The correspondence section (Letters to the Editor) includes various different 
types of letters. These include: BJD Research Letters; Rapid Response to 
Recently Published Original Articles (RRR-POA) published by the BJD; 
Opinion Pieces; Case Reports. 
All items of correspondence should be formatted in one continuous section, 
with no bulleted statements or abstract. The BJD regards Research Letters 
as its' most prestigious form of correspondence. These should not exceed 
1000 words, 15 references, two figures/tables. Rapid Response to Recently 
Published original articles should be scholarly, respectful to other authors, 
concise and to the point. They are intended to provide post-publication peer-
review; as such, these letters are important and are published by fast track. 
Letters that are opinion pieces are also welcome; this type of letter provides 
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an opportunity to publish original ideas, innovations, scholarly opinions, 
debates and controversies at an early stage of academic development; such 
pieces must also be concise. 
With the exception of Research Letters (see above), other forms of 
correspondence should not exceed 800 words, 10 references and two 
figures. Ideally, letters should be more concise than these limits. For all forms 
of correspondence, authors are advised to seek their own peer review by 
local scholars (who can be acknowledged) prior to submission. Additionally, 
all letters are subject to expert external peer review. 
 
Cover picture (New) 
 
The BJD is now seeking submissions for a new category of publication, the 
“cover picture” to be printed on the front cover of the journal. Photographs or 
images should be visually arresting, of high quality and of educational value. 
The image should be submitted with a concise, scholarly caption (of up to 
100 words) explaining the image, which will be printed on the inside of the 
front cover. Examples of potential cover pictures include clinical photographs 
of normal or diseased skin, images of a diagnostic technique (for example, 
histopathological images, immunostains, electron microscopy) or device or a 
historical image. Cover pictures will be selected for their visual impact, 
scientific merit, originality and relevance to the journal readership. 
 
Editorials/Commentaries 
 
Editorials and commentaries are typically commissioned by the Editors. 
However, suggestions for such articles are welcomed and should be directed 
to the Editorial Office. 
 
3. SUBMISSION OF MANUSCRIPTS 
 
All submissions should be made online at the BJD ScholarOne 
Manuscripts site (formerly known as Manuscript Central). New users should 
first create an account. Once a user is logged onto the site, submissions 
should be made via the Author Centre. 
 
Submissions must be accompanied by a completed Author Consent Form. 
Completed forms must be uploaded to ScholarOne Manuscripts at the same 
time as manuscript submission using file designation 'Supplementary files not 
for review'. 
 
4. PREPARATION OF MANUSCRIPTS 
 
Manuscripts must be written in British English. 
Manuscript text must be saved in Word (.doc or .docx) or Rich Text Format 
(.rtf). Do not submit text in PDF format (.pdf). Figures must be saved as 
separate figure files. GIF, JPEG, PICT or Bitmap files are acceptable for 
submission, but only TIFF or EPS files are suitable for printing. After 
acceptance, you will be contacted to provide print-quality figures if you have 
not already done so. NOTE: If you're able to supply figures PDF format (.pdf) 
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only they must be distilled using the 'Print Optimised' option. 
Abbreviations must be defined when first used in the abstract and in the main 
text, as well as when first used in table and figure captions. 
Manuscripts must be as succinct as possible. Repetition of information or 
data in different sections of the manuscript must be carefully avoided. Text 
must comply with the word limits defined in Section 2, and, where 
appropriate, include: 
 
Title Page 
The first page of all manuscripts should contain the following information: 
 
1) the title of the paper 
2) a running head not exceeding 70 characters (not needed for 
correspondence items) 
3) manuscript word, table and figure count 
4) names of authors as initial(s) followed by surnames 
5) names of the institutions at which the research was conducted, clearly 
linked to respective authors using superscript Arabic numbers 
6) name, address, telephone and fax number, and email address of 
corresponding author 
7) a statement of all funding sources that supported the work 
8) any conflict of interest disclosures (see Section 5) 
9) bulleted statements (maximum 70 words) in answer to each of the 
following questions: what's already known about this topic?; what does this 
study add? (Not applicable to Correspondence items.) 
 
Abstracts 
Authors submitting original articles should note that structured abstracts are 
required. The structured abstract should adopt the format: Background, 
Objectives, Methods, Results, Conclusions. 
Review articles and case reports require abstracts but they need not be 
structured. 
Abstracts should contain no citations to previously published work. 
Correspondence and gene corner articles do not require abstracts. 
 
Text 
This should in general, but not necessarily, be divided into sections with the 
headings: Summary, Introduction, Materials and Methods, Results, 
Discussion, Acknowledgments, References, Figure legends. 
 
Tables and Figures 
Tables should not be inserted in the appropriate place in the text but should 
be included at the end of the manuscript, each on a separate page. 
Figures must be submitted as a separate file or files. 
Tables and figures should be referred to in text as follows: Fig. 1, Figs 2–4; 
Table 1, Table 2. Each table and/or figure must have a legend that explains 
its purpose without reference to the text. Where a figure has more than one 
panel, each panel should be labelled in the top left-hand corner using lower 
case letters in parentheses, i.e. ‘(a)’, ‘(b)’ etc. and a brief description of each 
panel given in the figure legend. 
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Colour illustrations are welcomed and all colour is published free of charge to 
the author. 
Authors are themselves responsible for obtaining permission to reproduce 
previously published figures or tables. When an individual is identifiable in a 
photograph written permission must be obtained (see Section 5 below). 
 
Electronic Artwork 
Vector graphics (e.g. line artwork) should be saved in Encapsulated 
Postscript Format (EPS), and bitmap files (e.g. photographs) in Tagged 
Image File Format (TIFF). Line art must be scanned at a minimum of 800 dpi, 
photographs at a minimum of 300 dpi. 
 
References 
References should be in Vancouver format and appear as consecutive, 
unbracketed superscript numbers in the text, e.g. ‘in our previous reports1,2 
and those of Smith et al. 3–5' and should be listed numerically in the reference 
list at the end of the article. 
Format references as below, using standard (Medline) abbreviations for 
journal titles. If more than four authors, include the first three authors 
followed by et al. 
 
1 de Berker DAR, Baran R, Dawber RPR. The nail in dermatological 
diseases. In: Baran and Dawber's Diseases of the Nails and their 
Management(Baran R, Dawber RPR, de Berker DAR, Haneke E, Tosti A, 
eds), 3rd edn. Oxford: Blackwell Science Ltd, 2001; 172–92. 
 
2 Shuster S. The nature and consequence of Karl Marx’s skin disease. Br J 
Dermatol 2008; 158:1–3. 
 
3 Graham-Brown R, Burns T. Lecture Notes: Dermatology. Oxford: Wiley-
Blackwell, 2006. 
 
4 Smith A. (1999) Select committee report into social care in the community 
[WWW document]. URL http://www.dhss.gov.uk/reports/report015285.html 
[accessed on 7 November 2003]. 
 
We recommend the use of a tool such as EndNote for reference 
management and formatting. EndNote reference styles can be searched for 
here: http://www.endnote.com/support/enstyles.asp. 
 
Reporting Standards 
Manuscripts reporting randomised controlled trials (RCTs) must follow the 
CONSORT statement. RCTs will not be considered by BJD without 
submission of a completed CONSORT checklist. Checklists should be 
uploaded during manuscript submission using file designation 
'Supplementary files for review'. 
Manuscripts reporting observational studies must follow STROBE guidelines. 
Observational studies will not be considered by BJD without submission of a 
completed STROBE checklist (cohort studies, case-control studies, 
cross-sectional studies). Checklists should be uploaded during manuscript 
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submission using file designation 'Supplementary files for review'. 
 
Supporting Information 
BJD encourages the submission of underlying datasets, appendices, movie 
files, etc. as online-only supporting information. Supporting information 
should be uploaded during manuscript subission (see Section 3) using file 
designation 'Supplementary files for review'. 
Supporting information should be important ancillary information that is 
relevant to the parent article but which does not or cannot appear in the 
printed edition of the Journal. Supporting information will be published as 
submitted, and will not be corrected or checked for scienfitic content, 
typographical errors or functionality. 
 
5. DECLARATIONS 
 
Original Publication 
 
Submission of a manuscript will be held to imply that it contains original 
unpublished work and is not being submitted for publication elsewhere at the 
same time. The author must supply a full statement to the Editor about all 
submissions and previous reports that might be regarded as redundant or 
duplicate publication of the same or very similar work. BJD employs a 
plagiarism detection system. By submitting your manuscript, you accept that 
your manuscript may be screened for plagiarism against previously published 
works. 
 
Conflicts of Interest 
 
Authors are responsible for disclosing all financial and personal relationships 
between themselves and others that might be perceived by others as biasing 
their work. To prevent ambiguity, authors must state explicitly whether 
potential conflicts do or do not exist. 
 
Ethics 
 
When reporting experiments on human subjects, indicate whether the 
procedures followed were in accordance with the ethical standards of the 
responsible committee on human experimentation (institutional or regional) 
and with the Helsinki Declaration of 1975, as revised in 1983. Do not use 
patients' names, initials or hospital numbers, especially in illustrative material. 
When reporting experiments on animals, indicate whether the institution's or 
a national research council's guide for, or any national law on, the care and 
use of laboratory animals was followed. A statement describing explicitly the 
ethical background to the studies being reported should be included in all 
manuscripts in the Materials and Methods section. Ethics committee or 
institutional review board approval should be stated. 
Patients have a right to privacy that should not be infringed without informed 
consent. Identifying information should not be published in written 
descriptions, photographs and pedigrees unless the information is essential 
for scientific purposes and the patient (or parent or guardian) gives written 
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informed consent for publication. Identifying details should be omitted if they 
are not essential but patient data should never be altered or falsified in an 
attempt to attain anonymity. Complete anonymity is difficult to achieve and 
informed consent should be obtained if there is any doubt. For example, 
masking the eye region in photographs of patients is inadequate protection of 
anonymity. 
 
Authorship 
 
All persons designated as authors should qualify for authorship and all those 
who qualify should be listed. Each author should have participated 
sufficiently in the work to take public responsibility for appropriate portions of 
the content. One or more authors should take responsibility for the integrity of 
the work as a whole, from inception to published article. Authorship credit 
should be based only on 1) substantial contributions to conception and 
design, or acquisition of data, or analysis and interpretation of data; 2) 
drafting the article or revising it critically for important intellectual content; 3) 
final approval of the version to be published. Conditions 1, 2 and 3 must all 
be met. Acquisition of funding, the collection of data or general supervision of 
the research group, by themselves, do not justify authorship. All others who 
contributed to the work who are not authors should be named in the 
Acknowledgments section. 
 
Committee on Publication Ethics (COPE) 
 
As a member of the Committee on Publication Ethics (COPE), adherence to 
these submission criteria is considered essential for publication in the BJD; 
mandatory fields are included in the online submission process to ensure 
this. If, at a later stage in the submission process or even after publication, a 
manuscript or authors are found to have disregarded these criteria, it is the 
duty of the Editor to report this to COPE. COPE may recommend that action 
be taken, including but not exclusive to, informing the authors' professional 
regulatory body and/or institution of such a dereliction. 
The website for COPE may be accessed at: http://publicationethics.org 
 
 	
 	
 
 
 
 
 
 	
 
 
